Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
The susceptibility of human immunodeficiency virus type 2 (HIV-2) to protease inhibitors (PI) is largely unknown. We studied HIV-2 protease genes from 21 HIV-2-infected patients who were exposed or not exposed to PI. The aim of this study was (i). to characterize the polymorphism of HIV-2 protease in the absence of drug, (ii). to know whether the HIV-2 protease gene naturally harbors HIV-1 drug resistance codons, and (iii). to identify mutations emerging under PI-selective pressure. Sixty-five HIV-2 RNA or proviral DNA samples were directly sequenced from the plasma or peripheral blood mononuclear cells of 8 patients who had received PI and 13 patients who had never received any antiretroviral. In untreated patients, the highest amino acid variability in HIV-2 protease was observed at positions 14, 40, 43, 46, 65 and 70, and seven codons (10V, 32I, 36I, 46I, 47V, 71V, and 73A) associated with drug resistance in HIV-1 were highly prevalent. In addition, at six positions (positions 7, 46, 62, 71, 90, and 99), the amino acid variability or the amino acid frequencies or both differed significantly in PI-treated and untreated patients, suggesting that mutations 7K-->R, 46V-->I, 62V-->A/T, 71V-->I, 90L-->M and 99L-->F were occurring under PI-selective pressure. At these positions, at least one sample simultaneously harbored both wild-type and mutated codons, while substitutions at positions 62, 71, 90, and 99 were confirmed in a longitudinal analysis. Moreover, the presence of codons 46I and 99F in the absence of drug in HIV-2 subtype B proteases may reflect natural resistance to PI. In conclusion, the present study revealed that HIV-2 strains harbor specific patterns of natural polymorphism and resistance.
Colson
P
P
Laboratoire de Bactériologie-Virologie, Centre Hospitalo-Universitaire Timone et CNRS UMR 6020 IFR48, Université de la Méditerranée, Marseilles, France.
Henry
M
M
Tourres
C
C
Lozachmeur
D
D
Gallais
H
H
Gastaut
J A
JA
Moreau
J
J
Tamalet
C
C
D000328:Adult; D001483:Base Sequence; D016384:Consensus Sequence; D017931:DNA Primers; D004279:DNA, Viral / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D005260:Female; D005602:France; D015658:HIV Infections / Q000175:diagnosis* / Q000453:epidemiology; D016333:HIV Protease / Q000235:genetics*; D015498:HIV-2 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012367:RNA, Viral / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012725:Sexual Behavior
D017931:DNA Primers; D004279:DNA, Viral; D012367:RNA, Viral; D016333:HIV Protease